MedPath

The role of Image Enhancement Systems in the management of patients with non-muscle invasive bladder cancer

Completed
Conditions
on-muscle-invasive bladder cancer (NMIBC)
Cancer
Registration Number
ISRCTN90207346
Lead Sponsor
niversity of Crete, Medical School
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
211
Inclusion Criteria

Patients with suspected or confirmed NMIBC fulfilling the following inclusion criteria will be prospectively recruited in the study:
1. Prior WLI-TUR-NMIBC of primary or recurrent tumor(s)
2. Age =18 years
3. Written informed consent

Exclusion Criteria

1. Participation in a similar protocol
2. Absence of upper urinary tract tumors
3. Pregnancy/breastfeeding

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Recurrence rate detection of both the reference and index tests, using positive values for tumour recurrence and negative values for no tumour reoccurrence at 3, 9, 12, 18 and 24 months after WLI-TUR-NMIBC.
Secondary Outcome Measures
NameTimeMethod
To evaluate the contribution of each cystoscopy type (WLI vs SPIES) in the diagnosis of NMIBC in patients with positive urine cytology, via comparison of diagnosis rates between the two tests
© Copyright 2025. All Rights Reserved by MedPath